Risk factors

Sutro Biopharma carries substantial accumulated deficits and relies heavily on unproven cell-free and novel therapeutic platforms.

Ting Fiber subsidiary is heavily financed by term notes and preferred units, with substantial net losses and capital requirements. Heavy reliance on ICANN accreditations, domain registration rules, and evolving international data protection laws like GDPR. Telecom and wireless operations face FCC licensing and regulatory compliance risks.

Graf Global Corp. is a blank check company raising capital to complete an initial Business Combination without pre-identified targets.

Company faces risks from financing needs and material internal control weaknesses, Canadian and US cannabis market volatility, agricultural production hazards, and extensive regulatory dependencies.

Vuzix faces severe historical net losses and rising operating deficits totaling $367,522,950 as of December 31, 2024. The company relies heavily on discretionary customer purchase orders without long-term commitments. Operations depend critically on third-party component suppliers, micro-display technologies, and manufacturing facilities concentrated in West Henrietta, New York.

Revenue reached $204.3 million in 2024, driven by small business healthcare verticals like dental, optometry, and veterinary services. The company relies heavily on single-source suppliers like Stripe and GCP for payments and cloud infrastructure.

Revenue growth has slowed down to single digits recently, accompanied by historical net losses and an accumulated deficit of $707.1 million.

Zumiez relies heavily on mall traffic, vendor relationships, and discretionary spending in the competitive teen retail market.

Commercial UAS adoption, regulation, customer perception, and market growth are central risks to the company’s expansion.

AudioEye focuses heavily on digital accessibility software, facing ongoing net losses, capital needs, and integration challenges following its acquisition of ADA Site Compliance.

Amarin relies almost entirely on commercializing VASCEPA and VAZKEPA in the U.S. and Europe. Generic competition and ANDA litigation rulings have severely impacted U.S. revenues. International expansion faces stringent price controls, reimbursement hurdles, and reliance on third-party partners.

Alpha Pro Tech relies heavily on international manufacturing in Asia and Mexico, exposing it to tariffs and supply chain risks. Expiration of key patents in February 2024 threatens intellectual property protection and competitive advantage. The company faces high concentration and competitive pressures with limited control over joint venture operations in India.